Subacute sclerosing panencephalitis: promising results with intraventricular interferon alpha 2b therapy and intraventricular ribavarin therapy
Keywords:
Subacute sclerosing panencephalitis, Inosiplex, Ribavirin, Interferon-alpha (IFN-alpha)
Abstract
Subacute sclerosing panencephalitis (SSPE) is a devastating ‘slow virus’ disease of childhood and adolescence caused due to persistence of defective measles virus (MV) within the neurons and glial cells. Three drugs, i.e., inosiplex, ribavirin and interferon-alpha (IFN-alpha) were reported to be effective though none of them have been proven to be curative.
Downloads
Download data is not yet available.
References
1. Aulakh R, Tiwari A. Subacute sclerosing panencephalitis in a toddler: changing epidemiological trends. Case Rep Pediatr. 2013;341462. doi: 10.1155/2013/ 341462. Epub 2013 Dec 12.
2. Saha V, John TJ, Mukundan P, Gnanamuthu C, Prabhakar S, Arjundas G, et al. High incidence of subacute sclerosing panencephalitis in south India. Epidemiol Infect. 1990; 104:151–6
3. Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686–1693.
4. del Toro-Riera M, Macaya-Ruiz A, Raspall-Chaure M, Tallada-Serra M, Pasqual-López I, Roig-Quilis M et al. Subacute sclerosing panencephalitis: combined treatment with interferon alpha and intraventricular ribavirin. Rev Neurol. 2006 Mar 1-15;42(5):277-81.
5. Hara S, Kimura H, Hoshino Y, Hayashi N, Negoro T, Okumura A, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev.2003 Aug; 25 (5):367-9.
6. Hosoya M, Mori S, Tomoda A, Mori K, Sawaishi Y, Kimura H. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2004 Dec;48(12):4631-5.
7. Ghosh K.C, Bhattacharya R, Ghosh S, Mahata M, Das S, Das S, Mondal G.P. Comparative study of the outcome ofpediatric subacute sclerosing panencephalitis patients treated with oral ribavirin versus intraventricular interferon alpha 2b via Ommaya reservoir. Int J Pediatr Res. 2018;5(6):320-325.doi: 10.17511/ijpr.2018.6.04.
8. Miyazaki K, Hashimoto K, Suyama K, Sato M et al. Maintaining Concentration of Ribavirin in Cerebrospinal Fluid by a New Dosage Method; Three Cases of Subacute Sclerosing Panencephalitis Treated Using a Subcutaneous Continuous Infusion Pump. Pediatr Infect Dis J. 2018 Aug 27. doi: 10.1097/INF. 00000000 00002181. [Epub ahead of print]
2. Saha V, John TJ, Mukundan P, Gnanamuthu C, Prabhakar S, Arjundas G, et al. High incidence of subacute sclerosing panencephalitis in south India. Epidemiol Infect. 1990; 104:151–6
3. Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686–1693.
4. del Toro-Riera M, Macaya-Ruiz A, Raspall-Chaure M, Tallada-Serra M, Pasqual-López I, Roig-Quilis M et al. Subacute sclerosing panencephalitis: combined treatment with interferon alpha and intraventricular ribavirin. Rev Neurol. 2006 Mar 1-15;42(5):277-81.
5. Hara S, Kimura H, Hoshino Y, Hayashi N, Negoro T, Okumura A, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev.2003 Aug; 25 (5):367-9.
6. Hosoya M, Mori S, Tomoda A, Mori K, Sawaishi Y, Kimura H. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2004 Dec;48(12):4631-5.
7. Ghosh K.C, Bhattacharya R, Ghosh S, Mahata M, Das S, Das S, Mondal G.P. Comparative study of the outcome ofpediatric subacute sclerosing panencephalitis patients treated with oral ribavirin versus intraventricular interferon alpha 2b via Ommaya reservoir. Int J Pediatr Res. 2018;5(6):320-325.doi: 10.17511/ijpr.2018.6.04.
8. Miyazaki K, Hashimoto K, Suyama K, Sato M et al. Maintaining Concentration of Ribavirin in Cerebrospinal Fluid by a New Dosage Method; Three Cases of Subacute Sclerosing Panencephalitis Treated Using a Subcutaneous Continuous Infusion Pump. Pediatr Infect Dis J. 2018 Aug 27. doi: 10.1097/INF. 00000000 00002181. [Epub ahead of print]
CITATION
DOI: 10.17511/ijpr.2018.i06.01
Published: 2018-06-30
How to Cite
Dr. Roosy Aulakh. (2018). Subacute sclerosing panencephalitis: promising results with intraventricular interferon alpha 2b therapy and intraventricular ribavarin therapy. Pediatric Review: International Journal of Pediatric Research, 5(6), 306-307. https://doi.org/10.17511/ijpr.2018.i06.01
Issue
Section
Editorial
Copyright (c) 2018 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI - Open Archives Initiative
